Sostravel.com receives a research report by Arrowhead detailing a 2.76x potential upside in price
17.11.2022 10:00:00 EET | Business Wire | Press release
Sostravel.com S.p.A. (Euronext Growth Milan, ticker: SOS), digital operator offering booking services, digital itineraries including information on flights and airports, car rental, experiences, and proprietary services including the Lost Luggage Concierge through the Sostravel and Flio apps, as well as through the platforms www.Sostravel.com and www.amareitalia.com, announces that today, Arrowhead, an Independent Research company based in New York, providing due diligence and valuation reports on selected listed companies, published a research report on Sostravel, with a Fair Share Valuation Bracket of 2.01 to 2.50 EUR, when the share price of the company (ticker BIT: SOS) trades at ~0.90 EUR, for a 2,760% potential appreciation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006003/en/
Sostravel App offers booking services, digital itineraries including flight and airport information, car renting, experiences, and insurance services. The company operates the Lost Luggage Concierge proprietary service and is expanding into telehealth services designed for travellers. (Graphic: Business Wire)
Sostravel.com S.p.A. (SOS), headquartered in Italy, operates in the global travel and tourism (T&T) industry. It has a presence online, on Google Play, and Apple App Store, and in 23 airports in Europe, America, and Asia. The company was founded in 2017 as a spin-off from TraWell Co. (previously Safe Bag).
On November 1st, the company finalized the merger with DDC, a company with strong expertise in digital marketing for traveling and an established booking platform. The app, now merged with DDC allows customers to engage in bookings of airplanes, hotels, and cars, build a digital itinerary with other services, such as tours and events, and access value-added services like Lost Luggage Concierge and telehealth. The strategy is to attract potential customers with booking services and offer high-margin services through the app, focusing on the leisure and holiday segments.
The new post-merger entity is positioned to capture the growth in digital travel revenues, already owning a significant share of the passenger information sector, Sostravel aims to consolidate the world of traveler information and services, with the only integrated app on the market.
Based on its due diligence and valuation estimates, Arrowhead believes that SOS’s fair share value lies in the EUR 2 to EUR 2.50 bracket, which has been calculated using a blended valuation method: with 60% weighting to a discounted cash flow (DCF) method and 40% weighting to a Comparable Companies Valuation method.
Sostravel is listed on Euronext Growth Milan, ticker BIT: SOS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006003/en/
Contact information
For further information:
Sostravel.com S.p.A.
Investor Relations
Edoardo Zarghetta
investor.relations@Sostravel.com
www.Sostravel.com
Ph: +39 0331 1587117
Fax: +39 0331 1582452
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom